2006 Drug Trend Julayna Meyer, R.Ph, MBA Vice President Trend Management.

Slides:



Advertisements
Similar presentations
Market Analysis Learning Unit 3.
Advertisements

Commonwealth Connector Minimum Pharmacy Standards October 11, 2007.
Pharmacy Costs: “Can I Make a Difference?” September, 2014.
Solution in Drug Plan Management 2011 September 8, 2011 Basil Rowe Vice President, Total Rewards and Shared Services Shoppers Drug Mart
Utah All Payer Database (APD) Introduction to the Reporting Capabilities of the Utah All Payer Database Mark Gaskill, MFT Keely Cofrin.
Preparing for What’s on the Prescription Drug Benefit Horizon Brenda Motheral, PhD Senior Vice President Research & Product Management.
Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
The Cost Effectiveness of Direct to Consumer Advertising for Prescription Drugs Adam Atherly and Paul H. Rubin Emory University.
Commercial (Non Government Sponsored) Health Plan Medical Cost and Premium Trends Pharmaceuticals15%14% 12% 11%1.8% Hospital Inpatient Outpatient2515.
Presented by: Keenan & Associates Debra L. Yorba, Sr. Vice President February 22, 2014 License Plan Design Sub-Committee Recommendations KPPC/ESI.
FORECASTING PERFORMANCE Presented by: Teerachai Supojchalermkwan Krisna Soonsawad Chapter 11.
 2003 Express Scripts, Inc. All Rights Reserved The Medicare Prescription Drug Benefit and PBMs Barrett Toan Chief Executive Officer Express Scripts,
Impact of Multi-Tiered Copayments on Cost and Use of Prescription Drugs among the Elderly Presented at AcademyHealth Annual Research Meeting Presented.
Specialty Pharmacy: Today’s Prescription for a Better Tomorrow Steve Miller, MD Chief Medical Officer.
1 Generic Substitution in Medicare Part D Plans Jack Hoadley, Georgetown University Katie Merrell, Social & Scientific Systems Elizabeth Hargrave, NORC.
2 Entire contents © 2008 Forrester Research, Inc. All rights reserved. But what do benefit executives think about the current healthcare landscape?
PROPRIETARY AND CONFIDENTIAL Internal Strategic Pharmacy Programs Placemat Background 1  Prescriptions are the most frequently used health care benefit,
Unique & Creative Plan Design Suggestions to Help Control Costs
Credit Suisse First Boston Annual Healthcare Conference November 17, 2005.
SWITCHING OF MEDICINES 19 June SWITCH Reclassification of legal status of a medicine Typically one with many years of experience of safe use From.
Todd Hamilton District Sales Manager. Innovation  On average it takes scientists, physicians, engineers, and other researchers between 10 and 15 years.
Promoting high quality, cost effective drug therapy throughout the Military Health System Breaking Down Silos in Search of Value CAPT Mark A. Richerson,
Consumer-Driven Health Plans: Early Cost & Use Evidence with a Focus on Pharmaceuticals & Hospital Admissions Stephen T Parente Roger Feldman Jon B Christianson.
U.S. Drug Costs Dropped in 2012, but Rises Loom Katie Thomas The New York Times March 18, 2013
UMSYSTEM.EDU November 19, UMSYSTEM.EDU Missouri S&T Faculty Senate November 19, 2009.
William Blair 25 th Annual Growth Stock Conference June 16, 2005.
Potentials for drug savings in the generic sector - experience accross Europe" Per Troein Vice President Strategic Alliances IMS Health.
Inside the Black Box: How Actuaries Price Health Insurance Academy Health Annual Research Meeting June 8 th 2004 Lisa F. Tourville, ASA, MAAA Vice President.
Lehman Brothers 9th Annual Global Healthcare Conference March 8, 2006.
The Top 20 Drugs Your Dental Patient is Taking: Drug Interactions and Oral Manifestations Ronald S. Brown, DDS, MS.
Merck & Co., Inc. Recommendation Sell Yuqian(Annie) Zhang Nov. 4 th, 2004.
Title text here Consumer Perspective on Containing Drug Costs Leigh Purvis, Director, Health Services Research.
Consumer-Driven Health Plans: Early Cost & Use Evidence with a Focus on Pharmaceuticals Stephen T Parente Jon B Christianson Roger Feldman August, 2004.
New Analysis of DRE Savings for States & Federal Government September 22, 2008.
Evaluation of Virginia’s Preferred Drug List: 2 nd Quarter Interim Report Policy and Research Division June 22, 2004Department of Medical Assistance Services.
Walgreens Health Initiatives Maximizing Your Rx Drug Benefits Presented to Drury University Michele Pence Account Manager.
1  Expert pharmacy benefit management (PBM) consulting team  In-house pharmacists, PBM and Medicare Part D experts  Former C-level PBM executives averaging.
Can the Specialty Beast Be Tamed? Steven B. Miller, MD Express Scripts.
2007 Drug Trend Brian Seiz, PharmD Express Scripts.
Avalere Health LLC | The intersection of business strategy and public policy Part D Plans and Specialty Products Presented by Lovisa Gustafsson.
Copyright © 2009 Pearson Education, Inc. publishing as Prentice Hall2-1 Chapter Two Developing and Screening Business Ideas Dr. Bruce Barringer University.
Medication Therapy Management Program TML Intergovernmental Employee Benefits Pool.
Confidential and Proprietary Information © 2014 Express Scripts Holding Company. All Rights Reserved. 1 Confidential and Proprietary Information © 2014.
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015 Average annual growth rate of prescription drug spending per capita.
The Impact of Pipeline Drugs on Pharmaceutical Spending C. Daniel Mullins, Ph.D. Francis Palumbo, Ph.D., J.D. Bruce Stuart, Ph.D. University of Maryland.
The Cost of Reference-Priced Generic Drug Coverage.
Why are the Costs of Medications Increasing and What Can Be Done About It? William H. Shrank, M.D., M.S.H.S. April 15, 2016.
1 US.NMH © 2008 sanofi-aventis U.S. LLC Government Digest.
Source: Kaiser Family Foundation analysis of National Health Expenditure (NHE) Historical ( ) data from Centers for Medicare and Medicaid Services,
1 PROPRIETARY AND CONFIDENTIAL © 2013 Express Scripts Holding Company. All Rights Reserved. Your Collaborative Planning Guide State of Oklahoma April 9,
Confidential and Proprietary Information © 2012 Express Scripts, Inc. All Rights Reserved 1 AGING-RELATED MEDICATIONS: COST AND UTILIZATION PATTERNS Presenter:
Improving Value of Prescription Drug Dollars Gail Shearer Consumers Union BCBSA Briefing on Generic Drugs April 9, 2009.
Consumer Point-of-Care: What’s New in − 2 − © 2015 ZS Associates | CONFIDENTIAL The 2014 ZS study presented at the POC Summit last year estimated.
Ch 8 Monopoly. 2 Learning objectives  Appreciate how to gain market power.  For a seller with market power, identify the scale of production/sales that.
Peterson-Kaiser Health System Tracker What are the recent and forecasted trends in prescription drug spending?
Mental Health and Substance Abuse Prescription Drug Spending Trends: Medicaid and Privately Insured Populations American Public Health Association Annual.
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
Avocado Category Channel Overview
American Public Health Association Annual Meeting November 5, 2007
Changing Specialty Distribution to Clinical Management Models
Are Group Insurance Benefits Becoming Unaffordable?
The Basics of Pharmacy Benefit Management (PBM)
Express Scripts Exclusions Target 25 Drug Classes
2006 Healthcare Conference
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
Pharmacy – Fully Insured versus Self Funding
State of the pharmacy market
The Rx for Rx Savings Breaking the Status Quo!
How much is health spending expected to grow?
Millennial Avocado Shopper Trends
Presentation transcript:

2006 Drug Trend Julayna Meyer, R.Ph, MBA Vice President Trend Management

 2007 Express Scripts, Inc. All Rights Reserved Drug Trend I.Overall trend and spend II.Future Drug Trend Projections III.Key Therapy Classes IV.The Results of Active Management V.Ongoing opportunities to maximize the benefit

 2007 Express Scripts, Inc. All Rights Reserved Top DTC Advertised Classes $100 Million $200 Million $300 Million $400 Million $500 Million Source: JP Morgan March 19, 2007 Prescription Pad $179 Erectile Dysfunction $498 Hypnotics $446 Cholesterol $357 Asthma $221 Osteoporosis Hypnotics trend: 36.9%

 2007 Express Scripts, Inc. All Rights Reserved. 4 What Do We Mean By “Drug Trend”? We report total ingredient cost year over year –Plan design decisions determine cost-sharing We report Express Scripts commercial book of business –Plan specific results available through your Account Management team We track specialty separately More detailed information can be found in our Drug Trend Report

 2007 Express Scripts, Inc. All Rights Reserved. 5 Component 2001:022002:032003:042004:052005:06 Price Units per Rx Brand/Generic Mix Therapeutic Mix =Cost per Rx XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003 Price: The difference in average price per unit of common drugs compared to previous year. Typical drivers include market dynamics and competition.

 2007 Express Scripts, Inc. All Rights Reserved. 6 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx Brand/Generic Mix Therapeutic Mix =Cost per Rx XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 7 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx Brand/Generic Mix Therapeutic Mix =Cost per Rx XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 8 Brand Drug Prices Up Generic Drug Prices Down Brand Prices Up 6.9% Brand Price Leaders: Hypnotics up 13.8%Hypnotics up 13.8% Stimulants/obesity up 10.5%Stimulants/obesity up 10.5%

 2007 Express Scripts, Inc. All Rights Reserved. 9 Brand Drug Prices Up Generic Drug Prices Down Brand Prices Up 6.9%

 2007 Express Scripts, Inc. All Rights Reserved. 10 Brand Drug Prices Up Generic Drug Prices Down Brand Prices Up 6.9% Generic Prices Down 5.7%

 2007 Express Scripts, Inc. All Rights Reserved. 11 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix Therapeutic Mix =Cost per Rx XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 12 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix Therapeutic Mix =Cost per Rx XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003 Brand/Generic Mix: Reflects the cost impact of increased generic use. Typical drivers: new generics and maturation of the therapy class

 2007 Express Scripts, Inc. All Rights Reserved. 13 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix =Cost per Rx XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 14 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix =Cost per Rx XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 15 Top Brand/Generic Mix Changes RankTherapy Class Key Generic Introduction Therapy Class Impact 1AntihistaminesAllegra ® (2005)-11.8% 2NSAIDsMobic ® (2006)-10.7% 3DecongestantsFlonase ® (2006)-10.5% 4Narcotic Analgesics OxyContin ® (2005) Duragesic ® (2005) Actiq ® (2006) -9.1% 5Misc. HematologicsPlavix ® (2006)-8.3% 6Antihyperlipidemics Pravachol ® (2006) Zocor ® (2006) -5.6% 7AntidepressantsZoloft ® (2006)-2.5% Ranked by Percent Change

 2007 Express Scripts, Inc. All Rights Reserved. 16 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix =Cost per Rx XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003 Therapeutic Mix: Changes in the cost per Rx due to use of more or less expensive drugs and drug strengths. Typical drivers include new products replacing old products.

 2007 Express Scripts, Inc. All Rights Reserved. 17 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix 5.3%2.6%3.7%0.8%1.7% =Cost per Rx XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 18 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix 5.3%2.6%3.7%0.8%1.7% =Cost per Rx XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 19 Top Therapeutic Mix Changes Anticonvulsants Lyrica ® Lyrica ® 6.9% Antivirals Atripla ® Atripla ® 4.3% Beta Blockers Coreg CR TM, Toprol XL ® Coreg CR TM, Toprol XL ® 3.3% Dermatologics Elidel ® Elidel ® -2.4% Protopic ® Protopic ® NSAIDs COX-IIs COX-IIs -4.6% Ranked by Percent Change

 2007 Express Scripts, Inc. All Rights Reserved. 20 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix 5.3%2.6%3.7%0.8%1.7% =Cost per Rx 10.5%6.8%7.2%3.3%3.5% XUtilization =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 21 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix 5.3%2.6%3.7%0.8%1.7% =Cost per Rx 10.5%6.8%7.2%3.3%3.5% XUtilization 6.3%6.8%2.9%4.0%2.2% =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 22 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix 5.3%2.6%3.7%0.8%1.7% =Cost per Rx 10.5%6.8%7.2%3.3%3.5% XUtilization 6.3%6.8%2.9%4.0%2.2% =Common Drugs +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 23 Utilization Prevalence Proportion of members utilizing drugs Impacted by diagnosis and therapy plan 2006 Prevalence Trend: 1% Intensity Number of Rxs filled among utilizers Impacted by length of therapy 2006 Intensity Trend: 1.2%

 2007 Express Scripts, Inc. All Rights Reserved. 24 Lowest Utilization Increase in 5 Years % Change in Utilization

 2007 Express Scripts, Inc. All Rights Reserved. 25 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix 5.3%2.6%3.7%0.8%1.7% =Cost per Rx 10.5%6.8%7.2%3.3%3.5% XUtilization 6.3%6.8%2.9%4.0%2.2% =Common Drugs 17.5%14.0%10.4%7.5%5.8% +New Drugs Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 26 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix 5.3%2.6%3.7%0.8%1.7% =Cost per Rx 10.5%6.8%7.2%3.3%3.5% XUtilization 6.3%6.8%2.9%4.0%2.2% =Common Drugs 17.5%14.0%10.4%7.5%5.8% +New Drugs 1.0%0.5%0.3%0.4%0.2% Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 27 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix 5.3%2.6%3.7%0.8%1.7% =Cost per Rx 10.5%6.8%7.2%3.3%3.5% XUtilization 6.3%6.8%2.9%4.0%2.2% =Common Drugs 17.5%14.0%10.4%7.5%5.8% +New Drugs 1.0%0.5%0.3%0.4%0.2% Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 28 ~Three-fold Drop in New Drugs Compared to 1996 Nature Reviews Drug Discovery 6, (February 2007)

 2007 Express Scripts, Inc. All Rights Reserved. 29 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix 5.3%2.6%3.7%0.8%1.7% =Cost per Rx 10.5%6.8%7.2%3.3%3.5% XUtilization 6.3%6.8%2.9%4.0%2.2% =Common Drugs 17.5%14.0%10.4%7.5%5.8% +New Drugs 1.0%0.5%0.3%0.4%0.2% Overall Rx Trend Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2007 Express Scripts, Inc. All Rights Reserved. 30 Component 2001:022002:032003:042004:052005:06 Price 7.5%6.6%6.0%5.3%4.3% Units per Rx -0.1%0.3%0.2%0.1%0.4% Brand/Generic Mix -2.3%-2.6% -2.7%-2.9% Therapeutic Mix 5.3%2.6%3.7%0.8%1.7% =Cost per Rx 10.5%6.8%7.2%3.3%3.5% XUtilization 6.3%6.8%2.9%4.0%2.2% =Common Drugs 17.5%14.0%10.4%7.5%5.8% +New Drugs 1.0%0.5%0.3%0.4%0.2% Overall Rx Trend 18.5%14.5%10.6%7.9% 5.9% Components of Rx Cost Trend * * Excluding Specialty starting in 2003 ?

 2007 Express Scripts, Inc. All Rights Reserved. 31 Lowest Drug Trend In a Decade Express Scripts Internal Data, 2006 Note: Specialty tracked separately as of 2003 Drug Trend

 2007 Express Scripts, Inc. All Rights Reserved. 32 Lowest Drug Trend In a Decade Express Scripts Internal Data, 2006 Note: Specialty tracked separately as of % 60% 40% 20% 0% Generic Fill Rate Drug Trend

 2007 Express Scripts, Inc. All Rights Reserved. 33 Forecasted Single Digit Trends Through 2010 Projected non-specialty trends for ESI commercial plan sponsors actual, estimated 7.9%5.9%7.5%8.5%9.1%7.5%

 2007 Express Scripts, Inc. All Rights Reserved. 34 Brand Drugs Going Generic Soon More than $50 billion within the next five years Annual Sales $ Billion $11.2$10.2$8.6$12.8$8.5

 2007 Express Scripts, Inc. All Rights Reserved. 35 Brand Drugs Going Generic Soon More than $50 billion within the next five years Annual Sales $ Billion Zyrtec Wellbutrin XL Imitrex Ambien Norvasc Other Lamictal Risperdal Fosamax Effexor XR Advair* Other Valtrex Topamax Prevacid Other Cozaar Lipitor Other Levaquin Zyprexa Actos Protonix Other Toprol XL Adderall XR $11.2$10.2$8.6$12.8$8.5

 2007 Express Scripts, Inc. All Rights Reserved. 36 Top Five Therapy Classes Overall Total Ingredient Costs, 2005:2006 PMPY PMPY 3.6% 6.7% 7.1% 15.5% 11.6%

 2007 Express Scripts, Inc. All Rights Reserved. 37 0% 5% 10% 15% 20% 25% 30% Generic Antidepressant Market Share Gaps Jan 2001Jan 2002Jan 2003Jan 2004Jan 2005Jan 2006 citalopram actual paroxetine actual fluoxetine actual Without action, our SSRI generic use fell short by about 30% fluoxetine ideal paroxetine ideal citalopram ideal

 2007 Express Scripts, Inc. All Rights Reserved. 38 0% 5% 10% 15% 20% 25% 30% Generic Antidepressant Market Share Gaps Jan 2001Jan 2002Jan 2003Jan 2004Jan 2005Jan 2006 We didn’t want the same thing to happen in the biggest class -- Lipids citalopram actual paroxetine actual fluoxetine actual fluoxetine ideal paroxetine ideal citalopram ideal

2006 A Large Opportunity for Savings In the Statin Class

 2007 Express Scripts, Inc. All Rights Reserved. 40 Statin Market Shares Q Q Q Q % 60% 50% 40% 30% 20% 10% 0% Zocor Zocor gained market share prior to patent expiration

 2007 Express Scripts, Inc. All Rights Reserved. 41 Statin Market Shares Q Q Q Q % 60% 50% 40% 30% 20% 10% 0% Zocor Simvastatin Simvastatin continued on Zocor’s market growth curve

 2007 Express Scripts, Inc. All Rights Reserved. 42 Statin Market Shares Q Q Q Q % 60% 50% 40% 30% 20% 10% 0% Zocor Simvastatin Generic HMGs Generic drugs now lead the statin market.

 2007 Express Scripts, Inc. All Rights Reserved. 43 Express Scripts Outperformed The Nation Q Q Q Q % 60% 50% 40% 30% 20% 10% 0% ESI Generic HMGs NMS Generic HMGs

 2007 Express Scripts, Inc. All Rights Reserved. 44 Statin Trend Without GenericsToday With GenericsToday

 2007 Express Scripts, Inc. All Rights Reserved. 45 Statin Trend Without GenericsToday With GenericsToday +2.0%

 2007 Express Scripts, Inc. All Rights Reserved. 46 Statin Trend Without GenericsToday With GenericsToday -1.1% +2.0%

 2007 Express Scripts, Inc. All Rights Reserved. 47 Therapy Class #1: Lipids Generic Drugs Drove Down Trend Class Trend: 3.6% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price -5.6%

 2007 Express Scripts, Inc. All Rights Reserved. 48 Therapy Class #1: Lipids Generic Drugs Drove Down Trend Class Trend: 3.6% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price -5.6%

 2007 Express Scripts, Inc. All Rights Reserved. 49 Tremendous Generic Opportunity Class Trend: 6.7% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #2: Gastrointestinals

 2007 Express Scripts, Inc. All Rights Reserved. 50 Tremendous Generic Opportunity Class Trend: 6.7% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #2: Gastrointestinals ?

 2007 Express Scripts, Inc. All Rights Reserved. 51 Step Therapy Can Drive PPI Savings $44 $63 38% 14%

 2007 Express Scripts, Inc. All Rights Reserved. 52 Prevalence Drove Antidepressants Class Trend: 7.1% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #3: Antidepressants

 2007 Express Scripts, Inc. All Rights Reserved. 53 Prevalence Drove Antidepressants Class Trend: 7.1% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #3: Antidepressants

 2007 Express Scripts, Inc. All Rights Reserved. 54 Trend Driven By Prevalence Class Trend: 15.5% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #4: Diabetes

 2007 Express Scripts, Inc. All Rights Reserved. 55 Trend Driven By Prevalence Class Trend: 15.5% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #4: Diabetes

 2007 Express Scripts, Inc. All Rights Reserved. 56 Price Drove Asthma Class Trend: 11.6% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #5: Asthma

 2007 Express Scripts, Inc. All Rights Reserved. 57 Price Drove Asthma Class Trend: 11.6% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #5: Asthma

 2007 Express Scripts, Inc. All Rights Reserved. 58 Hypnotics Are Growing Quickly Class Trend: 36.9% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #19: Hypnotics

 2007 Express Scripts, Inc. All Rights Reserved. 59 Hypnotics Are Growing Quickly Class Trend: 36.9% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #19: Hypnotics

 2007 Express Scripts, Inc. All Rights Reserved. 60 Hypnotics Are Growing Quickly Class Trend: 36.9% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #19: Hypnotics

 2007 Express Scripts, Inc. All Rights Reserved. 61 Hypnotics Are Growing Quickly Class Trend: 36.9% New Drugs Intensity Prevalence Therapeutic Mix Brand/Generic Mix Price Therapy Class #19: Hypnotics

 2007 Express Scripts, Inc. All Rights Reserved. 62

 2007 Express Scripts, Inc. All Rights Reserved. 63

 2007 Express Scripts, Inc. All Rights Reserved. 64 Hypnotics Need Your Focus % 70% 60% 50% 40% 30% 20% 10% 0% Ambien Ambien CR Lunesta Sonata Rozerem

 2007 Express Scripts, Inc. All Rights Reserved. 65 Adding Programs Drives Savings >2 new programs 1 new program No new programs ESI 2006 Non-Specialty Trend: 5.9%

 2007 Express Scripts, Inc. All Rights Reserved. 66 Adding Programs Drives Savings >2 new programs 1 new program No new programs

 2007 Express Scripts, Inc. All Rights Reserved. 67 Adding Programs Drives Savings >2 new programs 1 new program No new programs

 2007 Express Scripts, Inc. All Rights Reserved. 68 Adding Programs Drives Savings >2 new programs 1 new program No new programs

 2007 Express Scripts, Inc. All Rights Reserved Trend At An Encouraging 5.9% The more you manage, the lower your trend. Opportunities abound for managing out waste. –PPI class represents a significant opportunity –Don’t be asleep with Hypnotics spend